Arkolith/Insider Trading/CTMX/Form 4

Belvin Marcia

SVP, Chief Scientific OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4 · filed Mar 21, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$27K
Net Open-Market Flow
-$27K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 19, 2024Sell(S)13K$2.09$27K169K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000176) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML